Cision Vision

Cision Vision, founded in 2020 as a spinoff from MIT, is revolutionizing the field of pathology with its innovative imaging technology. The company specializes in helping pathologist's assistants and pathology residents process lymph nodes quickly and accurately, even for the smallest nodes in treated cases. The core technology, developed by CEO Dr. Jeremy Li and Prof. Angela Belcher, leverages the natural chemical composition contrast between lymph nodes and surrounding fat to provide high-contrast, real-time imaging without the need for injections or radiation.

Cision Vision's device is compact, about the size of a shoebox, making it suitable for even the most space-constrained laboratories. It is battery-operated, allowing for easy mobility within the lab environment. The system can save images to local disks and integrate them into pathology reports, enhancing the efficiency and accuracy of lymph node analysis.

The primary market for Cision Vision includes pathologist's assistants, pathology residents, and other clinicians who require precise and rapid lymph node imaging. The company operates within the medical imaging and pathology sectors, focusing on improving the quality and consistency of patient care.

Cision Vision's business model is based on the sale of its imaging devices to medical institutions and laboratories. The company generates revenue through the direct sale of these units, as well as potential service agreements for maintenance and software updates.

The company has received significant support from the pathology community, having engaged with over four hundred professionals to refine its technology and ensure it meets the needs of its users. Cision Vision aims to modernize pathology grossing and contribute to high-quality care for millions of patients worldwide.

Keywords: lymph node imaging, pathology, real-time imaging, medical device, MIT spinoff, compact design, battery-operated, high contrast, patient care, pathology reports.